Teva appoints two to executive team

Friday, August 3, 2012 11:07 AM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has appointed Dr. Carlo De Notaristefani as president and CEO of global operations and Aharon (Arik) Yaari as executive vice president of newly created community and institutional affairs.

De Notaristefani has over 25 years of international experience with extensive technical, operational, manufacturing and P&L experience. Most recently, De Notaristefani was at Bristol-Myers Squibb (BMS) where he served as president of technical operations and global support functions. Before joining BMS, he held several senior positions in manufacturing and supply chain at Aventis Pharmaceuticals. Earlier in his career, De Notaristefani held positions at Hoechst Marion Roussel, Marion Merrell Dow and Dow Chemical.

Yaari joined Teva in 1981 and has served as group vice president of global API, and most recently as group vice president of Teva generics systems. In his new position, Yaari will execute on Teva’s global commitment to social responsibility, philanthropy, institutional affairs and academic relations.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private á¼€nancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs